In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In
Part 1 patients with melanoma will receive AdCD40L as mono therapy. In Part 2A, patients with
melanoma and patients with other solid tumors will receive AdCD40L in combination with low
dose cyclophosphamide. In Part 2B, patients with melanoma will receive AdCD40L in combination
with one local radiotherapy and cyclophosphamide.